Clicky

CSL Limited(CMXHF)

Description: CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.


Keywords: Disorders Influenza Neurological Disorders Blood Hereditary Angioedema Angioedema Blood Plasma Antitrypsin Deficiency Complement Deficiency Csl Behring Csl Limited Behring Non Plasma Biotherapeutic Products Biopharmaceutical And Allied Biopharmaceutical And Allied Products Bleeding Disorders Csl Treatment Of Immunodeficiency

Home Page: www.csl.com.au

45 Poplar Road
Parkville, VIC 3052
Australia
Phone: 61 3 9389 1911


Officers

Name Title
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer
Dr. Paul F. McKenzie Ph.D. COO & Exec. Director
Mr. Mark Dehring Head of Investor Relations
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel
Christina Hickie Sr. Mang. of Communications
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production
Ms. Jemimah Brennan Head of Communications - Asia Pacific

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 43.1034
Trailing PE: 41.2009
Price-to-Book MRQ: 6.6463
Price-to-Sales TTM: 9.304
IPO Date:
Fiscal Year End: June
Full Time Employees: 30000
Back to stocks